Chemical Information | |
Antiviral agent ID | DrugRepV_6157 | |
Antiviral agent name | Schisandrin A | |
IUPAC Name | (9R,10S)-3,4,5,14,15,16-hexamethoxy-9,10-dimethyltricyclo[10.4.0.02,7]hexadeca-1(16),2,4,6,12,14-hexaene | |
SMILES (canonical) | CC1CC2=CC(=C(C(=C2C3=C(C(=C(C=C3CC1C)OC)OC)OC)OC)OC)OC | |
SMILES (isomeric) | C[C@@H]1CC2=CC(=C(C(=C2C3=C(C(=C(C=C3C[C@@H]1C)OC)OC)OC)OC)OC)OC | |
Molecular Formula | C24H32O6 | |
Molecular Weight (g/mol) | 416.514 | |
InChl | InChI=1S/C24H32O6/c1-13-9-15-11-17(25-3)21(27-5)23(29-7)19(15)20-16(10-14(13)2)12-18(26-4)22(28-6)24(20)30-8/h11-14H,9-10H2,1-8H3/t13-,14+ | |
Structural Information | |
|
|
Clinical Information | |
Biological Information | |
Secondary Indication | Dengue virus (DENV) NA NA | |
Secondary Indication (Approaches) | Experimental | |
Secondary Indication (Methods) | In-vitro | |
Secondary Indication (Model system) [cell lines/ animal models] | Huh-7
| |
Secondary Indication (Mode of drug delivery) | Culture
| |
Secondary Indication (Time of drug delivery) | Post infection
| |
Secondary Indication (Duration of drug delivery) | 6 days
| |
Secondary Indication (Drug concentration) | 5 mg/kg
| |
Secondary Indication (Cell based assay) | Survival assay
| |
Secondary Indication (Change) | Decrease
| |
Secondary Indication (Survival rate) | 80 | |
Reference | Yu JS, Wu YH, Tseng CK, Lin CK, Hsu YC, Chen YH, Lee JC..Schisandrin A inhibits dengue viral replication via upregulating antiviral interferon responses through STAT signaling pathway..Sci Rep. 2017 Mar 24;7:45171. doi: 10.1038/srep45171. PubMed Central PMCID: PMC5364541. PMID:28338050
| |
Comment | Schisandrin A can e ectively protect mice from DENV infection by reducing disease symptoms and mortality of DENV-infected mice.
| |